Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials

Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials

Objective To investigate the clinical efficacy and toxicity of Pemetrexed versus Gefitinib as second-line treatment for advanced non-small cell lung cancer (NSCLC).

Bibliographic Details
Main Authors: Wang Huiyu, Zhang Zunjing, Liu Feng, Zhou Miaoying, Lv Handi
Format: Article
Language:English
Published: De Gruyter 2019-12-01
Series:Pteridines
Subjects:
pemetrexed
gefitinib
non-small cell lung cancer
meta-analysis
Online Access:https://doi.org/10.1515/pteridines-2019-0022

Internet

https://doi.org/10.1515/pteridines-2019-0022

Similar Items